Bipolar affective disorder is a severe mood disorder that afflicts approximately 1% of the population worldwide. Twin and adoption studies have indicated that genetic factors contribute to the disorder and while many chromosomal regions have been implicated, no susceptibility genes have been identified. We undertook a combined analysis of 10 cM genome screen data from a single large bipolar affective disorder pedigree, for which we have previously reported linkage to chromosome 13q14 (Badenhop et al, 2001) and 12 pedigrees independently screened using the same 400 microsatellite markers. This 13-pedigree cohort consisted of 231 individuals, including 69 affected members. Two-point LOD score analysis was carried out under heterogeneity for three diagnostic and four genetic models. Non-parametric multipoint analysis was carried out on regions of interest. Two-point heterogeneity LOD scores (HLODs) greater than 1.5 were obtained for 11 markers across the genome, with HLODs greater than 2.0 obtained for four of these markers. The strongest evidence for linkage was at 3q25-26 with a genome-wide maximum score of 2.49 at D3S1279. Six markers across a 50 cM region at 3q25-26 gave HLODs greater than 1.5, with three of these markers producing scores greater than 2.0. Multipoint analysis indicated a 20 cM peak between markers D3S1569 and D3S1614 with a maximum NPL of 2.8 (P = 0.004). Three other chromosomal regions yielded evidence for linkage: 9q31-q33, 13q14 and 19q12-q13. The regions on chromosomes 3q and 13q have previously been implicated in other bipolar and schizophrenia studies. In addition, several individual pedigrees gave LOD scores greater than 1.5 for previously reported bipolar susceptibility loci on chromosomes 18p11, 18q12, 22q11 and 8p22-23.
Introduction
Bipolar affective disorder (MIM 125480) affects approximately 1% of the population worldwide 1 and is the sixth highest cause of disability globally. 2 The etiology of bipolar disorder remains unknown, but family, twin and adoption studies have indicated that genetic factors contribute significantly to the disorder. 3, 4 Family studies indicate that there is a seven-fold increase in the risk to first-degree relatives while twin studies show that there is an average four-fold increase in risk for monozygotic vs dizygotic twins. 3, 4 The mode of inheritance remains unclear but it is likely that the disorder is oligogenic and heterogeneous with multiple loci of modest effect.
While initial genetic linkage studies of bipolar disorder were fraught with inconsistencies and failures to replicate, more recently the accumulation of multiple studies on large pedigree cohorts has led to reproducible identification of several susceptibility loci. These include regions on chromosomes 4, 12q, 18, 21q and 22q. [5] [6] [7] [8] [9] [10] We have previously reported evidence for linkage to chromosome 4q35 11 and 13q14. 12 Both of these findings were generated from genome screen analyses of single large pedigrees. Several groups have since reported support for the 4q35 locus [13] [14] [15] in other bipolar cohorts and the 13q14 locus in studies of both bipolar disorder [16] [17] [18] and schizophrenia [19] [20] [21] pedigrees. We have performed a genome screen analysis on a further 12 medium to large bipolar affective pedigrees. As these 12 pedigrees were analysed with the same marker set as the pedigree for which we reported linkage to 13q14, 12 we have combined the analysis of the genome screen data. In the present paper, we present the results of the combined analysis of these 13 bipolar affective disorder pedigrees.
Subjects and methods

Family ascertainment
The pedigrees used in this study were ascertained as part of an ongoing bipolar genetics study via the Mood Disorders Unit, Prince of Wales Hospital/University of New South Wales, Sydney, Australia. Medium to large multigenerational pedigrees with illness over at least two generations and containing a minimum of three affected individuals (at least two of whom were diagnosed with bipolar I) were recruited. Families were Caucasian and almost entirely of British or Irish descent. The families were assessed using the Diagnostic Interview for Genetic Studies (DIGS) 22 and best-estimate Research Diagnostic Criteria (RDC) diagnoses were made after independent evaluation of interviews and medical records. All marrying-in individuals were routinely questioned about any family history of psychiatric illness to ensure unilateral descent of bipolar disorder in the pedigrees. Individuals who participated in the study provided appropriate informed written consent. The study was approved by the Ethics Committee of the University of New South Wales.
The pedigree cohort in the present study was comprised of 13 pedigrees made up of 293 members of whom 231 were available for analysis, including 69 affected individuals (Figure 1 ) of which Ped 04 (40 individuals including six affecteds) has previously been reported. 12 In total there were 33 individuals diagnosed with bipolar I (BPI), seven with schizoaffective disorder manic type (SZ/MA), four with bipolar II (BPII) and 25 with recurrent unipolar depression (UP). The average number of individuals per pedigree was 17.7 with the average number of affected individuals per pedigree being 5.3.
Genotyping DNA was extracted from whole blood using a standard salting-out method. All samples were genotyped with 400 microsatellite markers from the ABI PRISM Linkage Mapping Set Version 2 (Applied Biosystems, Foster City, CA, USA). The markers in this mapping set had an average heterozygosity of 0.79 and were spaced at approximately 10 cM intervals across the genome. Genotyping was carried out at the Australian Genome Research Facility, Melbourne, Australia (www.agrf. org.au). Some additional microsatellite markers were analysed on chromosome 3q25. The markers at 3q25 were identified using the chromosome 3 summary map from The Genetic Location DataBase (LDB). Primer sequences, expected-size information and known allele frequencies for most markers were obtained from The Genome Database (GDB) (http://gdbwww.gdb.org/). The markers and their GDB accession numbers are D3S1309 (GDB:188504), D3S1593 (GDB:199848), D3S3606 (GDB:609402), D3S1555 (GDB:199255) and D3S3637 (GDB:610608).
PCR of the additional markers was carried out in a 15 l volume containing 60 ng DNA, 250 M dNTPs, 0.33 M of each primer (the forward primer labelled with 6-FAM fluorescent dye), 2.5 mM MgCl 2 , 1 × PCR buffer and 0.6 units AmpliTaq Gold polymerase Molecular Psychiatry (Applied Biosystems). PCR reactions were carried out on a Hybaid OmniGene thermal cycler (Hybaid, Middlesex, UK) using the following protocol; 95°C for 12 min, 30 cycles of 95°C for 30 s, either 58°C or 60°C for 30 s, 72°C for 30 s, 72°C for 5 min. One and a half microlitres of the PCR product were mixed with loading dye (2.5 l formamide, 0.5 l of 50 mg ml −1 blue dextran : 50 mM EDTA, 0.5 l GeneScan500 Tamra size standard). Samples were loaded onto a 4% polyacrylamide gel and electrophoresis was carried out on an ABI PRISM 377 DNA Sequencer. Products were detected using the GeneScan Analysis program, version 3.1 and alleles were assigned using the Genotyper program, version 2.5 (Applied Biosystems). Marker typing incompatibilities were detected using the PedCheck program, version 1.0.
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Statistical analysis
Two-point LOD score analysis was carried out using the ANALYZE package. 24 LOD score analysis was carried out under heterogeneity to take into account the possibility of interfamilial heterogeneity. Three disease models were used in the analysis. In disease model I, individuals diagnosed with either BPI or SZ/MA were classified as affected and all other family members were classified as unaffected. In the disease model II, individuals diagnosed with either BPI, SZ/MA or BPII were classified as affected and all other family members were considered unaffected. In the disease model III, individuals diagnosed with either BPI, SZ/MA, BPII or UP were classified as affected and all other family members were considered unaffected. Four liability classes (class 1, Ͻ20 years; class 2, 20-29 years; class 3, 30-39 years and class 4, Ͼ40 years) were used in the analysis with maximum age-specific penetrance levels of either 60% or 90%. In the 90% model, liability classes were defined with penetrances of 0.18, 0.45, 0.68 and 0.9; those in the 60% model were defined with penetrances of 0.12, 0.30, 0.45 and 0.6. The data were analyzed under both dominant and recessive inheritance models. The disease-allele frequency was set at 0.035 for the dominant model and 0.2 for the recessive model, and a phenocopy rate of 5% was used in all analyses. Marker allele frequencies were calculated from the data using the DOWNFREQ program from the ANALYZE package 24 using all individuals. Recombination fractions were converted from centimorgan distances provided on the ABI/CHLC integrated map (http://lpg.nci.nih.gov/html-chlc/Chlc Maps.html).
Simulation analyses using SLINK and MSIM 25, 26 were performed on these pedigrees to aid in the interpretation of results. Simulation analyses were performed under both dominant and recessive models at both 60% and 90% maximum age-dependent penetrance and for the three different disease models using a 6 allele marker and 1000 replicates. In order to determine the minimum LOD score required to select markers for further analysis, we determined the maximum expected LOD scores of the cohort under the assump- tion of no linkage. Under the assumption of no linkage the maximum expected LOD score ranged from 0.9 to 1.8 (depending on the model) with an average of 1.3, and no power to detect a LOD score greater than 3.0. In comparison, the maximum expected LOD score for the entire pedigree cohort under the assumption of homogeneity ranged from 1.8 to 8.5 with an average of 4.7, and 40% power to detect a LOD score greater than 3.0. Under the assumption of 50% heterogeneity the maximum expected LOD score ranged from 1.4 to 5.3 with an average of 2.9, and 5% power to detect a LOD score greater than 3.0. Based on the results of the simulations, markers giving LOD scores greater than 1.5 from the analysis of the genome data were subjected to an initial review. These selected markers were discarded from any further analysis if they had flanking markers which gave negative LOD scores, or the positive LOD scores obtained were only under a single disease or genetic model. After this initial review of the data three regions were selected for analysis using multipoint analysis in order to define any potential regions of linkage. Non-parametric multipoint analyses were performed using GENEHUNTER.
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Results
The results of the two-point score analysis under heterogeneity are shown in Figure 2 . Two-point heterogeneity LOD scores (HLODs) greater than 1.5 were obtained for 11 markers across the genome, with HLOD scores greater than 2.0 obtained for four of these markers ( Table 1 ). The strongest evidence for linkage was on chromosome 3q25-q26. A genome-wide maximum HLOD score of 2.49 ( = 0, ␣ = 1) was obtained at marker D3S1279 under a 60% dominant model, for the disease model I. A HLOD of 1.5 ( = 0, ␣ = 0.23) was obtained at the adjacent marker, D3S1614, under a 90% dominant model and the disease model I.
Five additional markers at 3q25-q26 were genotyped in the 13 pedigrees ( Figure 3 ). HLODs greater than 1.0 were obtained for four of these markers spanning 50 cM. Of the additional markers genotyped, HLODs greater than 2.0 were obtained for D3S1593 (2.3, = 0, ␣ = 0.23) and D3S1555 (2.5, = 0, ␣ = 0.63) and HLODs greater than 1.5 were obtained for D3S3637 (1.9, = 0, ␣ = 0.58) and D3S1309 (1.6, = 0.12, ␣ = 1.0). The positive HLODs for the chromosome 3 markers were largely obtained under the narrower disease models I or II and a dominant model. While HLODs for the chromosome 3 markers were also positive under diagnostic model III, no marker gave a score greater than 1.5 under this model.
As the results for marker D3S1614 were at an alpha value of 0.23, LOD scores for individual pedigrees were inspected at this marker. A single large pedigree (pedigree 05) was found to contribute to the positive score at D3S1614 with a maximum LOD score of 2.38 ( = 0). Positive HLODs of all other markers were obtained at higher alpha values with several families contributing to the positive scores at these markers.
Non-parametric multipoint analysis of the ABI PRISM Linkage Mapping Set Version 2 markers was carried out in order to define the potential disease region. From this analysis, a maximum NPL score of 2.8 (P = 0.004) was obtained between D3S1569 and D3S1614 under a diagnostic model II (Figure 4a ). Multipoint analysis using the five additional markers genotyped in this cohort did not further refine the region. Table 1 shows other regions on chromosomes 9, 13 and 19 which yielded evidence for linkage. There are two regions on chromosome 9 for which HLODs greater than 1.5 were obtained; D9S285 (1.64, = 0, ␣ = 0.4) at 9p22 and markers D9S1776 (1.74, = 0.16, ␣ = 1) and D9S1690 (1.60, = 0.0, ␣ = 0.81) at 9q31-q33 (Table 1) . At 9p22 there were several markers which gave HLODs greater than 1.0 across a 30 cM region, including markMolecular Psychiatry ers D9S157 and D9S171. All positive HLODs at 9p22 were obtained under disease model III. Similarly multiple markers at 9q31-q33 gave HLODs greater than 1.0 across a 50 cM region, including D9S287 and D9S290. The maximum HLODs for the 9q31-q33 markers were all obtained under disease model III, although small positive scores were also seen for all these markers under the narrower disease models I and II. The regions on chromosome 9 are separated by approximately 60 cM. Non-parametric multipoint analysis of chromosome 9 shows a peak between D9S1690 and D9S1677 at 9q31-q33 with a maximum NPL of 2.5 (P = 0.02) under diagnostic model III (Figure 4b ).
There were two markers at 13p11-q14 which gave HLODs greater than 1.5; D13S153 (2.29, = 0, ␣ = 0.26) at 13q14 under a 90% recessive model and disease model III and D13S175 (1.9, = 0, ␣ = 0.74) at 13p11 under a 60% recessive model and disease model I. The positive score at D13S153, obtained at an alpha value of 0.26, can be attributed to the single large pedigree (pedigree 04) for which we have previously reported linkage to this locus. 12 Several other markers spanning a 80 cM region on 13q gave HLODs greater than 1.0 in the cohort, including D13S218 (1.14, = 0, ␣ = 0.21), D13S263 (1.15, = 0.14, ␣ = 1.0), D13S156 (1.28, = 0, ␣ = 0.37) and D13S173 (1.43, = 0.18, ␣ = 1.0). The maximum HLODs for the 13q markers were all obtained under a recessive model and disease model III, although small positive scores were also seen for all these markers under the narrower disease models I and II. Inspection of the LOD scores for individual pedigrees at the 13q markers revealed that pedigree 04 was the only pedigree contributing to the positive scores at markers D13S218 and D13S156, while there were several positive families for markers D13S175 and D13S263. Analysis of the chromosome 13 markers in the cohort excluding pedigree 04, gave HLODs greater than 1.0 for two markers: D13S175 (1.15, = 0.0, ␣ = 0.63) and D13S173 (1.04, = 0.2, ␣ = 1.0).
There are several markers spanning chromosome 19 which gave HLODs greater than 1.0. A marker flanking D19S216 (1.55, = 0.18, ␣ = 1.0), D19S209, gave a HLOD of 1.12 also under a recessive model and disease model III while three markers: D19S220, D19S420 and D19S571 some 65 cM from D19S216 also gave HLODs greater than 1.0 but under a dominant model and disease model III. Small positive HLOD scores were also seen for the chromosome 19 markers under the narrower disease models I and II. Non-parametric multipoint analysis of chromosome 19 gave a peak of 4.55 (P = 0.0002) between markers D19S414 and D19S220 at 19q12-q13 under diagnostic model III. There is a smaller positive peak (NPL = 1.33, P = 0.09) observed between D19S216 and D19S84 at 19p13 (Figure 4c ). While the NPL score at 19q12-q13 is significant, the HLODs are modest and therefore inconsistent with the significance indicated by the multipoint analysis. Multipoint analysis is not as robust to the presence of errors as two-point analysis, and can result in an inaccurate estimation of the location of the disease-prediposing gene. 28 Therefore we have taken a more con- servative approach in the interpretation of these results and consider the evidence for linkage to 19q based on the HLODs to be weak in comparison to other loci in our study. HLODs greater than 1.5 were also obtained for markers D7S507, D8S514 and DXS986 (Table 1) . However the absence of supporting data from flanking markers or positive scores under the multiple models tested, indicated that these are unlikely to be true positive results. In addition to the findings in the entire cohort, there were individual pedigrees which gave LOD scores greater than 1.5 at loci previously reported in other genome screens of bipolar cohorts (Table 2 ). These included regions on chromosomes 18, 22 and 8. 
Discussion
We have examined genome screen data for 400 markers in 13 medium to large bipolar pedigrees. While we did not identify any regions of significant linkage, there were several regions of interest for which suggestive linkage, according to the criteria established by Lander and Kruglyak, 30 is indicated. The genome-wide maximum was a HLOD of 2.49 at D3S1279 on chromosome 3q25-q26 under a narrow diagnostic model and an autosomal dominant inheritance model. Other potential regions included loci on chromosomes 9q, 13q and 19q and support for existing bipolar loci on chromosomes 8p, 18p, 18q and 22q.
From a previous genome screen analysis of a single large pedigree (pedigree 04), 12 LOD scores greater than 1.0 were obtained for four markers on chromosome 3q25-q26, including D3S1292, D3S1278, D3S1279 and D3S1569. In the present study, we provide additional support for this locus in a larger pedigree cohort and with additional markers. At chromosome 3q25-q26 there were six markers across 50 cM which gave HLODs greater than 1.5, with three markers giving LOD scores greater than 2.0. Nonparametric multipoint analysis indicated a peak between markers D3S1569 and D3S1614, a region of approximately 20 cM. The region on 3q25-q26 has also been implicated in a recent study by Kelsoe et al. 10 In a genome screen of 20 North American pedigrees, Kelsoe et al 10 identified two regions on chromosome 3, at 3p21 and 3q27, with LOD scores greater than 2.0. The region implicated by
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Kelsoe et al 10 overlaps the region identified in our analysis. The maximum LOD scores reported by Kelsoe et al 10 were found under a narrow diagnostic model, including only BPI individuals as affected, with a dominant mode of inheritance, as was found in our analysis.
Chromosome 13q has been implicated in multiple studies of both bipolar disorder [16] [17] [18] and schizophrenia [19] [20] [21] cohorts. In our study, the positive scores for the 13q markers appear to be largely due to a single pedigree (pedigree 04) in which we have previously reported linkage. 12 Analysis of pedigree 04 gave a maximum two-point LOD score of 2.91 at D13S153 and a maximum NPL score of 4.09 (P = 0.008) between markers D13S1272 and D13S153. There is also some evidence for linkage to this region in the other pedigrees analysed, although this is at D13S175 (13p11), approximately 40 cM from the region implicated in pedigree 04. It is of interest that there are now several overlapping loci implicated in both bipolar disorder and schizophrenia, including loci on 22q, 10, 31 18p, 32 10p 29 as well as 13q. [16] [17] [18] [19] [20] [21] The overlap in loci indicated by linkage studies raises the possibility that there are common susceptibility genes for these disorders, suggesting that the disorders may be related with heterogeneous underlying etiologies due to different combinations of common genetic and environmental factors.
Few studies have implicated chromosome 9q31-q33 in bipolar disorder. The exception is Detera-Wadleigh et al 33 who reported evidence for increased allele sharing at D9S302 (P = 0.004) on chromosome 9q33 in the 97 pedigree cohort from the National Institute of Mental Health Genetics Initiative. This region is of interest as it contains the candidate gene, dopamine betahydroxylase, an enzyme involved in dopamine neurotransmission. There have been no reports of linkage to chromosome 19 which could represent a novel locus for susceptibility to bipolar disorder.
Clearly the number of possible susceptibility loci identified to date provide strong evidence that bipolar disorder is multigenic and subject to genetic heterogeneity. If there is significant heterogeneity, this could explain the failure of genome screens of large cohorts of smaller sized pedigrees 13, 34 to identify loci that meet the criteria for an initial finding of significant linkage. This may be due to the presence of multiple independently segregating susceptibility loci. Conversely, genome screens of large multigenerational pedigrees have provided the most compelling evidence for linkage of bipolar disorder to a locus. 5, 6, 9, 11 The most likely explanation is that within a single large pedigree, where the locus is of modest effect, the other susceptibility loci could be largely homozygous such that one is able to observe evidence for linkage for that single segregating locus. In this context, it is of interest that there were several individual pedigrees in our cohort which provided support for linkage to known bipolar susceptibility loci at 18p11, 8 18q12, 7 22q11 10 and 8p22-23.
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In each of these individual pedigrees, the LOD scores obtained at these known loci were the maximum obtained for that pedigree across the genome.
In our analysis of a genome screen of 13 medium to large bipolar pedigrees the strongest evidence for linkage was at 3q25-q26, with three other chromosomal regions, 9q31-q33, 13q14 and 19q12-13 yielding evidence for linkage and individual pedigrees providing support for existing bipolar loci at 18p11, 18q12, 22q11 and 8p22-23. The regions on 3q25-q26, 9q31-q33 and 13q14 have previously been implicated in other bipolar disorder genome screens, while the region on 19q12-13 may represent a novel bipolar susceptibility locus. Although several of these regions satisfy the criteria for suggestive linkage, none are significant. The strength of the results, however, must be interpreted relative to other regions of the genome for which no evidence for linkage was found and also in the context of continuing support for loci identified in genome screen of other bipolar cohorts.
